Thermo Fisher Scientific Inc. $TMO Stake Cut by Legacy Wealth Management LLC MS

Legacy Wealth Management LLC MS reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,356 shares of the medical research company’s stock after selling 1,427 shares during the period. Thermo Fisher Scientific comprises about 1.2% of Legacy Wealth Management LLC MS’s holdings, making the stock its 18th largest holding. Legacy Wealth Management LLC MS’s holdings in Thermo Fisher Scientific were worth $3,793,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mondrian Investment Partners LTD lifted its stake in Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after acquiring an additional 127,357 shares in the last quarter. GAMMA Investing LLC boosted its position in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. United Services Automobile Association acquired a new stake in Thermo Fisher Scientific during the first quarter valued at $4,395,000. Ilmarinen Mutual Pension Insurance Co boosted its position in Thermo Fisher Scientific by 5.3% during the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company’s stock valued at $33,488,000 after purchasing an additional 3,400 shares during the last quarter. Finally, Cetera Trust Company N.A boosted its position in Thermo Fisher Scientific by 3.3% during the first quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company’s stock valued at $2,312,000 after purchasing an additional 150 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $479.48 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market capitalization of $181.06 billion, a PE ratio of 27.73, a P/E/G ratio of 2.62 and a beta of 0.75. The stock has a 50-day simple moving average of $466.86 and a 200 day simple moving average of $451.65.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Analyst Ratings Changes

A number of analysts recently issued reports on TMO shares. Barclays raised Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $490.00 to $550.00 in a research report on Thursday. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Evercore ISI reduced their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. William Blair started coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Finally, Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $592.24.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.